Depression is a multifactorial neurological and psychiatric disorder characterized by persistent sadness, loss of interest, and emotional imbalance. It affects mood, cognition, and physical health, disrupting neurotransmitter systems such as serotonin, dopamine, and norepinephrine. Increasingly, depression is recognized not only as a mental-health issue but also as a neurobiological condition involving complex brain-network dysfunctions.

The Depression session explores the molecular, genetic, and environmental determinants of depressive disorders, examining how chronic stress, inflammation, and neurochemical dysregulation alter neural circuits. Research integrates neuroimaging, electrophysiology, and genomics to reveal biomarkers that can predict susceptibility and treatment response.

At the Depression Research Conference, scientists present breakthroughs in pharmacological and non-pharmacological interventions. Discussions include SSRIs, SNRIs, ketamine infusions, and novel psychedelic-based therapies that target synaptic plasticity. Additionally, brain-stimulation techniques such as transcranial magnetic stimulation (TMS) and deep-brain stimulation are transforming treatment for refractory depression.

This session is designed for psychiatrists, neurologists, psychologists, and neuroscientists aiming to bridge biological research with clinical applications. Topics extend to digital mental-health solutions, neurofeedback therapy, and AI-based screening tools for early diagnosis.

Insights from Neuropsychiatry are continuously redefining depression as a disorder of brain circuitry—linking mood, cognition, and neuroplasticity to holistic wellbeing.